Business
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the latest findings on time savings with continued treatment with humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab (generic name, U.S. brand name LEQEMBI®) were presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference. Additionally, a s
About this update from Eisai Co., Ltd.
[{"type":"text","content":"Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer's disease by up to 8.3 years in low-amyloid group who started treatment at an early stage","length":233,"tagName":"p","attribs":{}},{"type":"text","content":"New safety and efficacy data presented at scientific symposium on subcutaneous formulation for LEQEMBI initiation treatment, which is under regulatory review in the United States ","length":178,"tagName":"p","attribs":{}},{"type":"text","content":"TOKYO and CAMBRIDGE, Mass., Dec. 3, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the latest findings on time savings with continued treatment with humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab (generic name, U.S. brand name LEQEMBI®) were presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference. Additionally, a scientific symposium was held on the subcutaneous formulation (SC-AI), which was approved for maintenance treatment in the United States in August 2025, and the rolling supplemental Biologics License Application (sBLA) for initiation treatment was completed in November 2025. The application for a subcutaneous injectable formulation in Japan was submitted in November 2025.","length":959,"tagName":"p"},{"type":"image","alt":"Eisai logo and Biogen logo (PRNewsfoto/Eisai Co., Ltd.)","displaySize":"","headline":null,"caption":"Eisai logo and Biogen logo (PRNewsfoto/Eisai Co., Ltd.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":112,"url":"https://media.zenfs.com/en/prnewswire.com/8fbe328e0f2d5337d2839c8345101b15"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0o85llr4k4YPB6fanxtHPg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE5NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/8fbe328e0f2d5337d2839c8345101b15","width":400,"height":112}},"href":"https://mma.prnewswire.com/media/723010/Eisai_Logo_and_Biogen_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Alzheimer's disease (AD) is a progressive, relentless disease with Aβ and tau as hallmarks, that is ...